|
|
|
|
LEADER |
00000cam a2200000Mu 4500 |
001 |
EBSCO_ocn779141401 |
003 |
OCoLC |
005 |
20231017213018.0 |
006 |
m o d |
007 |
cr |n|---||||| |
008 |
120305s2012 xx o 000 0 eng d |
040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d N$T
|d YDXCP
|d BENTH
|d OCLCQ
|d OCLCO
|d OCLCQ
|d D6H
|d OCLCQ
|d AGLDB
|d ZCU
|d MERUC
|d OCLCQ
|d VTS
|d ICG
|d VT2
|d OCLCQ
|d WYU
|d S9I
|d JBG
|d STF
|d DKC
|d OCLCQ
|d M8D
|d OCLCQ
|d AJS
|d OCLCO
|d OCLCQ
|
019 |
|
|
|a 1264898817
|
020 |
|
|
|a 9781608052974
|q (electronic bk.)
|
020 |
|
|
|a 1608052974
|q (electronic bk.)
|
029 |
1 |
|
|a AU@
|b 000055795740
|
029 |
1 |
|
|a DEBBG
|b BV042793121
|
029 |
1 |
|
|a DEBBG
|b BV044162580
|
029 |
1 |
|
|a DEBSZ
|b 472595458
|
035 |
|
|
|a (OCoLC)779141401
|z (OCoLC)1264898817
|
050 |
|
4 |
|a RC280.B6
|
072 |
|
7 |
|a HEA
|x 039030
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 062000
|2 bisacsh
|
082 |
0 |
4 |
|a 616.99/418
|a 616.99418
|
049 |
|
|
|a UAMI
|
100 |
1 |
|
|a Podar, Klaus.
|
245 |
1 |
0 |
|a Multiple Myeloma - A New Era of Treatment Strategies.
|
260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2012.
|
300 |
|
|
|a 1 online resource (217 pages)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a data file
|2 rda
|
505 |
0 |
|
|a 01 Multiple Myeloma -- A New Era of Treatment Strategies.pdf; 02 Cover Page; 03 REVISED eBooks End User License Agreement-Website; 04 TABLE OF CONTENTS; 05 Foreword; 06 PREFACE; 07 Contributors; 08 Section 1; 09 Chapter 01; 10 Chapter 02; 11 Chapter 03; 12 Section 2; 13 Chapter 04; 14 Chapter 05; 15 Chapter 06; 16 Chapter 07; 17 Chapter 08; 18 Section 3; 19 Chapter 9; 20 Chapter 10; 21 Chapter 11; 22 Section 4; 23 Chapter 12; 24 Chapter 13; 25 INDEX.
|
520 |
|
|
|a Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cell.
|
588 |
0 |
|
|a Print version record.
|
590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
650 |
|
0 |
|a Multiple myeloma
|x Treatment.
|
650 |
|
6 |
|a Myélome multiple
|x Traitement.
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x Cancer.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Oncology.
|2 bisacsh
|
700 |
1 |
|
|a Anderson, Kenneth C.
|
776 |
0 |
8 |
|i Print version:
|a Podar, Klaus.
|t Multiple Myeloma - A New Era of Treatment Strategies.
|d Sharjah : Bentham Science Publishers, ©2012
|
856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=500767
|z Texto completo
|
938 |
|
|
|a Bentham Science Publisher
|b BENT
|n 9781608052974
|
938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL864207
|
938 |
|
|
|a EBSCOhost
|b EBSC
|n 500767
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 7465282
|
994 |
|
|
|a 92
|b IZTAP
|